# What will Hims & Hers Health, Inc. say during their next earnings call

> Testosterone leads at 94%, runner-up 92% across 14 winner-take-all outcomes — refreshed 3 min ago.

URL: https://simplefunctions.dev/odds/earningsmentionhims
Updated: 2026-05-09T05:50:41.998Z
Category: general
Status: active
Closes: 2026-09-30

## Headline

- Leader: Testosterone at 94%
- Runner-up: Peptide at 92%
- Outcomes: 14 (winner-take-all)
- Venue: Kalshi (14 contracts)
- 24h volume: $3K

## Bound contracts (14)

| Outcome | Price | 24h | Volume | Venue | Slug |
|---|---|---|---|---|---|
| Testosterone | 94¢ | +6pp | $238 | kalshi | /markets/what-will-hims-hers-health-inc-say-during-their-ne-kalshi-kxearningsmentionhims-26may11-test |
| Peptide | 92¢ | +4pp | $79 | kalshi | /markets/what-will-hims-hers-health-inc-say-during-their-ne-kalshi-kxearningsmentionhims-26may11-pept |
| FDA | 86¢ | +6pp | $412 | kalshi | /markets/what-will-hims-hers-health-inc-say-during-their-ne-kalshi-kxearningsmentionhims-26may11-fda |
| Lab Testing | 84¢ | +23pp | $310 | kalshi | /markets/what-will-hims-hers-health-inc-say-during-their-ne-kalshi-kxearningsmentionhims-26may11-labt |
| Canada | 76¢ | +10pp | $281 | kalshi | /markets/what-will-hims-hers-health-inc-say-during-their-ne-kalshi-kxearningsmentionhims-26may11-cana |
| Zava | 72¢ | +4pp | $250 | kalshi | /markets/what-will-hims-hers-health-inc-say-during-their-ne-kalshi-kxearningsmentionhims-26may11-zava |
| Collaboration | 69¢ | +2pp | $710 | kalshi | /markets/what-will-hims-hers-health-inc-say-during-their-ne-kalshi-kxearningsmentionhims-26may11-coll |
| Vitamin | 50¢ | +9pp | $323 | kalshi | /markets/what-will-hims-hers-health-inc-say-during-their-ne-kalshi-kxearningsmentionhims-26may11-vita |
| Regulation | 41¢ | −5pp | $255 | kalshi | /markets/what-will-hims-hers-health-inc-say-during-their-ne-kalshi-kxearningsmentionhims-26may11-regu |
| Europe | 34¢ | +3pp | $2 | kalshi | /markets/what-will-hims-hers-health-inc-say-during-their-ne-kalshi-kxearningsmentionhims-26may11-euro |
| Cancer | 32¢ | +3pp | $260 | kalshi | /markets/what-will-hims-hers-health-inc-say-during-their-ne-kalshi-kxearningsmentionhims-26may11-canc |
| Amazon | 25¢ | +13pp | $39 | kalshi | /markets/what-will-hims-hers-health-inc-say-during-their-ne-kalshi-kxearningsmentionhims-26may11-amaz |
| Microdose / Microdosing | 16¢ | +13pp | $155 | kalshi | /markets/what-will-hims-hers-health-inc-say-during-their-ne-kalshi-kxearningsmentionhims-26may11-micr |
| Tariff | 3¢ | +4pp | $20 | kalshi | /markets/what-will-hims-hers-health-inc-say-during-their-ne-kalshi-kxearningsmentionhims-26may11-tari |

## 30-day trajectory

| Day | Testosterone | Peptide | FDA |
|---|---|---|---|
| 2026-05-07 | 59 | 58 | 64 |
| 2026-05-08 | 88 | 83 | 77 |
| 2026-05-09 | 94 | 87 | 83 |

_3 days of price history captured. Each row is the daily mean of intraday 5-min captures._

## What moved the line

- 2026-05-08 · Regulation +44pp 11→55¢ · kalshi
- 2026-05-08 · Canada +30pp 38→68¢ · kalshi
- 2026-05-08 · Testosterone +29pp 59→88¢ · kalshi
- 2026-05-08 · Collaboration +27pp 32→59¢ · kalshi
- 2026-05-08 · Peptide +25pp 58→83¢ · kalshi

## Analysis

This probability reflects market participants' collective assessment that peptide-related commentary will be the dominant topic during Hims & Hers Health's next earnings call, priced at 86 cents. The high confidence in peptide discussion reflects both the company's known focus on GLP-1 agonists and similar weight-loss compounds, as well as investor appetite for exposure to this market segment. Close runners-up on testosterone (83¢) and lab testing (77¢) suggest meaningful uncertainty about which product category receives emphasis. The key driver moving this probability will be management's actual statements during the earnings call itself—the timing of which depends on when Hims & Hers announces their next quarterly results. Secondary factors include recent company announcements about peptide availability, competitive developments in the telehealth weight-loss space, and any regulatory changes affecting these product categories prior to the call.

### Key factors

- Hims & Hers' peptide/GLP-1 agonist revenue and growth rate relative to other product lines in their most recent reported quarter
- Competitive activity in telehealth-delivered weight-loss medications during the period preceding the earnings call
- Recent or pending regulatory actions affecting peptide availability, compounding rules, or telehealth restrictions
- The company's stated strategic priorities in previous earnings calls and investor communications
- The specific date and timing of the next scheduled earnings announcement, which determines when resolution occurs

## Methodology

Headline is the **leader's price**, not an arithmetic mean — averaging disjoint winner-take-all outcomes is meaningless. Per-outcome prices come from the venue's last-traded mid; cross-venue values are simple means across contracts on each venue.

## How to use this data

- HTML: https://simplefunctions.dev/odds/earningsmentionhims
- JSON: https://simplefunctions.dev/api/public/odds?slug=earningsmentionhims

## License

CC-BY-4.0. Attribute "SimpleFunctions" with a link to https://simplefunctions.dev. See https://simplefunctions.dev/legal for terms.